UNLOCKING THE POWER OF NIK TO TRANSFORM THE FUTURE OF CANCER AND AUTOIMMUNE DISEASE TREATMENT.
Targeting NIK, a key regulator of the non-canonical NF-κB pathway, holds immense therapeutic potential in cancer and autoimmune diseases.
NIK
(NF-κB-inducing kinase)
NIK BLOCKERS
CANCER
AUTOIMMUNEDISEASE
Mission Statement
At Nikaia Pharmaceuticals, our mission is to revolutionize the treatment of cancer and autoimmune diseases through innovative NIK (NF-κB-inducing kinase) targeted therapies.
We are developing highly selective NIK blockers that address disease at its root, offering new hope to patients with limited treatment options.
Through cutting-edge research and a patient-centered approach, we aim to deliver therapies that restore immune balance, reduce inflammation, and combat disease progression. Our work is driven by the profound belief that groundbreaking science can unlock a healthier future for all.
About us
Founded in May 2024, Nikaia Pharmaceuticals is a pioneering biotech company dedicated to transforming the treatment of cancer and autoimmune diseases through NIK (NF-κB-inducing kinase) targeting.
Science
Targeting NIK, a key regulator of the non-canonical NF-κB pathway, holds immense therapeutic potential in cancer and autoimmune diseases.